DOPA AS AN ANTIMETABOLITE IN HUNTINGTON'S DISEASE

Fred Baskin, RogerN Rosenberg

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A point mutation affecting the primary structure of an enzyme which usually distinguishes between dopa or a dopa metabolite and tyrosine could explain the neuronal cell death which is characteristic of Huntington's disease. The dopa metabolite would then act as an antimetabolite, inhibiting the tyrosine t-R.N.A. acylation step, blocking protein synthesis, and eventually causing cell death.

Original languageEnglish (US)
Pages (from-to)582-583
Number of pages2
JournalThe Lancet
Volume301
Issue number7803
DOIs
StatePublished - Mar 17 1973

Fingerprint

Antimetabolites
Dihydroxyphenylalanine
Huntington Disease
Tyrosine
Cell Death
Acylation
Point Mutation
RNA
Enzymes
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DOPA AS AN ANTIMETABOLITE IN HUNTINGTON'S DISEASE. / Baskin, Fred; Rosenberg, RogerN.

In: The Lancet, Vol. 301, No. 7803, 17.03.1973, p. 582-583.

Research output: Contribution to journalArticle

Baskin, Fred ; Rosenberg, RogerN. / DOPA AS AN ANTIMETABOLITE IN HUNTINGTON'S DISEASE. In: The Lancet. 1973 ; Vol. 301, No. 7803. pp. 582-583.
@article{8f12ba59c52140949f218a54d4e1eebf,
title = "DOPA AS AN ANTIMETABOLITE IN HUNTINGTON'S DISEASE",
abstract = "A point mutation affecting the primary structure of an enzyme which usually distinguishes between dopa or a dopa metabolite and tyrosine could explain the neuronal cell death which is characteristic of Huntington's disease. The dopa metabolite would then act as an antimetabolite, inhibiting the tyrosine t-R.N.A. acylation step, blocking protein synthesis, and eventually causing cell death.",
author = "Fred Baskin and RogerN Rosenberg",
year = "1973",
month = "3",
day = "17",
doi = "10.1016/S0140-6736(73)90722-8",
language = "English (US)",
volume = "301",
pages = "582--583",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7803",

}

TY - JOUR

T1 - DOPA AS AN ANTIMETABOLITE IN HUNTINGTON'S DISEASE

AU - Baskin, Fred

AU - Rosenberg, RogerN

PY - 1973/3/17

Y1 - 1973/3/17

N2 - A point mutation affecting the primary structure of an enzyme which usually distinguishes between dopa or a dopa metabolite and tyrosine could explain the neuronal cell death which is characteristic of Huntington's disease. The dopa metabolite would then act as an antimetabolite, inhibiting the tyrosine t-R.N.A. acylation step, blocking protein synthesis, and eventually causing cell death.

AB - A point mutation affecting the primary structure of an enzyme which usually distinguishes between dopa or a dopa metabolite and tyrosine could explain the neuronal cell death which is characteristic of Huntington's disease. The dopa metabolite would then act as an antimetabolite, inhibiting the tyrosine t-R.N.A. acylation step, blocking protein synthesis, and eventually causing cell death.

UR - http://www.scopus.com/inward/record.url?scp=0015928334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015928334&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(73)90722-8

DO - 10.1016/S0140-6736(73)90722-8

M3 - Article

C2 - 4120646

AN - SCOPUS:0015928334

VL - 301

SP - 582

EP - 583

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7803

ER -